#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary neuropathic amyloidosis Pleural mesothelioma malignant Gastric cancer Meningococcal immunisation Stress cardiomyopathy Cutaneous T-cell lymphoma refractory Small cell lung cancer recurrent Primitive neuroectodermal tumour Arteriosclerosis Adrenoleukodystrophy Chronic myeloid leukaemia Thrombocytosis Pulmonary sarcoidosis Metastatic malignant melanoma Frostbite More trials…

    Learn about Rare Diseases

    Methylmalonic acidaemia – Life with Disease Atypical haemolytic uraemic syndrome – Treatment X-linked lymphoproliferative syndrome – Treatment Rhabdomyosarcoma – Trials in Disease Cholangitis sclerosing Breast angiosarcoma metastatic – Life with Disease Hereditary angioedema with C1 esterase inhibitor deficiency – Basic Information Antithrombin III deficiency Haemophilia B with anti factor IX – Life with Disease Medulloblastoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Candesartan Cilexetil Ecoo6A Temocillin Sodium Aficamten Febuxostat Hemihydrate Carbamazepine (Ph. Eur.) Maraviroc OMEGA-3-ACID ETHYL ESTERS 90 Sodium 2-Hydroxylinoleate Canis Familiaris (553) Ibuprofen Diclofenac Diethylamine Florbetaben (18F) Opium, Standardized Powdered Promazine Hydrochloride Colistin Sulfate BI 456906 Palbociclib Gr0015 Octreotide Hydrochloride More therapies…

    Learn about Your Condition

    Erythema migrans Joint stabilisation Scoliosis Precocious puberty Peripheral artery angioplasty Arteriosclerosis Facial paresis Alexander disease Hepatitis alcoholic Cancer pain Infertility female Drug use disorder Anal cancer metastatic Post-acute COVID-19 syndrome Lymphocytic lymphoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Multiple sclerosis

  • Study on the Safety and Effectiveness of Fingolimod and Interferon Beta-1a in Children with Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Fingolimod
    France Germany Romania Slovakia Spain

  • Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Clinically isolated syndrome
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    Germany Spain

  • Study on the Effects of SAR443820 and Gadobutrol in Patients with Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Oditrasertib
    • Gadobutrol
    Belgium Bulgaria France Germany Italy Poland +1

  • Study Comparing Subcutaneous and Intravenous Ocrelizumab for Patients with Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Ocrelizumab
    Czechia Italy Poland Spain

  • Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    Austria Belgium Bulgaria Croatia Czechia Estonia +14

  • Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Fingolimod Hydrochloride
    • Ofatumumab
    • Siponimod Fumaric Acid
    Austria Belgium Croatia Estonia France Germany +7
Previous Page
1 … 6 7 8 9 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!